Glucagon-Like peptide 1/glucagon receptor dual agonism reverses obesity in mice
One researcher, Beverly Tchang, suggested that using multiple pathways, as Retatrutide does, is the best way forward due to obesitys complexities
The mechanisms of DSPN are not fully understood but involve downstream injurious pathways associated with hyperglycaemia, dyslipidaemia and microvascular disease leading to neuronal inflammation, oxidative stress, mitochondrial dysfunction and cell death
Some people experience headaches on GLP-1 medications accompanied by scalp tenderness
no regulatory approval exists as of April 2026 Side effects are primarily gastrointestinal, dose-dependent, and generally manageable with gradual dose escalation It is not commercially available through legitimate channels